Innovative Modular Manufacturing Facility
BLIS Technologies to Install Innovative Modular Manufacturing Facility
BLIS Technologies Limited today announced plans to construct a dedicated manufacturing unit based on the innovative standards-based design concept of Kiwi company, Modular Containment Units Limited (MCU). The controlled environment unit, developed specifically for the manufacture of BLIS Technologies’ beneficial bacteria-based product range, will be installed in Nelson at Alaron Products, the GMP (Good Manufacturing Practice) accredited contract manufacturer which produces BLIS K12 Throat Guard.
MCU has applied for patent rights to develop modular containment units, based on interdisciplinary standards, which provide a controlled environment for use by biotechnology and medical industries. The facility will comply with the New Zealand, Australian and US FDA requirements for laboratory design as well as codes of GMP for the manufacture of therapeutic, biotechnological and medicinal products.
“The throughput of BLIS Technologies expanded product range has now reached a level where it is more efficient and cost-effective for us to use dedicated facilities rather than share facilities used for the production of other products. This specialised facility is being installed in the expectation that further growth in markets and products will continue,” BLIS Technologies Chief Executive Kelvin Moffatt said.
“The beauty of this modular concept is that it leaves expansion options open for the future while addressing our current needs in a cost effective manner.”
“Our modular approach enables us to provide a flexible, purpose-built facility for BLIS that will provide a very high level of manufacturing assurance compliant with New Zealand, Australian and US design and manufacturing standards,” said Daz Pettus, MCU Director.
In May 2002 BLIS successfully launched BLIS K12 Throat Guard, containing a beneficial bacterium which assists in maintaining throat health by supporting the body’s natural defences against undesirable bacteria.
In March this year the second product was launched, BLIS Bio RESTORE, a world-first solution for restoring naturally occurring beneficial oral and intestinal bacteria following antibiotic use.
BLIS Technologies has also lodged a patent for a product containing a bacterium that assists in preventing tooth decay. This product is about to undergo clinical trials in association with the University of Otago Dental School, with recruitment for the trial currently underway.
Additionally the company recently announced an application for a provisional patent on bacterial strains for the prevention of ear and sinus infections.
Technologies owns the rights to an extensive range of BLIS
producing organisms and intends developing more new products
for use in the control of undesirable bacterial infections,
including areas such as bad breath (halitosis), skin
infections such as acne and the prevention and treatment of